Adaptation and implementation of the ARK (Antibiotic Review Kit) Intervention to safely and substantially reduce antibiotic use in hospitals: A feasibility study


* These authors contributed equally.

1 Brighton and Sussex Medical School, University of Sussex, Falmer, UK
2 Centre for Clinical and Community Applications of Health Psychology, University of Southampton, Southampton, UK
3 Oxford University Hospitals NHS Foundation Trust, Oxford, UK
4 Nuffield Department of Medicine, University of Oxford, Oxford, UK
5 NIHR Biomedical Centre, Oxford, UK
6 School of Psychological Science, University of Bristol, Bristol, UK

Corresponding author: Prof Martin Llewelyn, Brighton and Sussex Medical School, University of Sussex, Falmer, East Sussex BN1 9PS UK, m.j.llewelyn@bsms.ac.uk, +44 (0)1273 876671

Declarations of interest: none

SHORT RUNNING TITLE: Antibiotic Review Kit Feasibility Study
Structured summary

Background
Antimicrobial stewardship initiatives in secondary care depend on clinicians undertaking antibiotic prescription reviews but decisions to limit antibiotic treatment at review are complex.

Aim
To assess the feasibility and acceptability of implementing ARK (Antibiotic Review Kit), a behaviour change intervention made up of four components (brief online tool, prescribing decision aid, regular data collection and feedback process, and patient leaflet) to support stopping antibiotic treatment when it is safe to do so among hospitalised patients; before definitive evaluation through a stepped-wedge cluster randomised controlled trial.

Methods
Acceptability of the different intervention elements was assessed over 12-weeks by uptake of the online tool, adoption of the decision aid into prescribing practice, and rates of decisions to stop antibiotics at review (assessed through repeated point-prevalence surveys). Patient perceptions of the information leaflet were assessed through a brief questionnaire.

Findings
All elements of the intervention were successfully introduced into practice. A total of 132 staff encompassing a broad range of prescribers and non-prescribers completed the online tool (19.4 per 100 acute beds), including 97% (32/33) of the pre-specified essential clinical staff. Among 588 prescription charts evaluated in seven point prevalence surveys over the 12-week
implementation period, 82% overall (76-90% at each survey) used the decision aid. The median antibiotic stop rate post implementation was 36% (range 29-40% at each survey) compared with 9% pre implementation (p<0.001).

Conclusion

ARK provides a feasible and acceptable mechanism to support stopping antibiotics safely at post-prescription reviews in an acute hospital setting.

Keywords: Antimicrobial stewardship, prescribing practice, antibiotic usage
Introduction

Hospital prescribing accounts for a minority of human antibiotic consumption but is where the great majority of broad-spectrum antibiotics are prescribed. Reducing antibiotic overuse in hospitals is challenging because patients who present acutely unwell or are critically ill require prompt and adequate initial antibiotic therapy. Controlling antibiotic overuse relies on regular review and revision of antibiotic prescribing decisions; in the UK National Health Service (NHS) ‘Start Smart then Focus’ guides that the continued need for antibiotics is assessed at 24-72 hours when more diagnostic information is available and treatment response can be assessed. Similarly, recommendations from the USA Centers for Disease Control and Prevention (CDC) include antibiotic “time-outs” to prompt reassessment of the continued need for and choice of antibiotic treatment.

Wide-ranging educational and practice resources exist to support hospital antibiotic stewardship but significant improvements in hospital antibiotic overprescribing have not been achieved. Knowledge, system and behavioral factors combine to make it very hard for doctors to take active decisions to stop antibiotics and under 10% of antibiotic prescriptions are discontinued at review in the NHS. For these reasons, the Antibiotic Review Kit (ARK) intervention was designed and carefully optimised using an integrated person-based approach to address the barriers to behaviour change (Santillo et al., Journal of Antimicrobial Chemotherapy in press). ARK aims to support prescribing and non-prescribing healthcare professionals apply the “review and revise” approach to antibiotic prescriptions for acute and general medical inpatients, and specifically to stop antibiotic treatment more often when it is safe to do so.
The clinical impact of many research programmes evaluating novel antimicrobial prescribing interventions is hampered by design and reporting limitations. In particular all stages of evaluation should be reported allowing clinicians to understand how potential barriers and facilitators have been considered. Ahead of the definitive evaluation of ARK in a multi-centre in a stepped-wedge cluster randomised trial we undertook a single-site feasibility study. Here we report the practicalities of implementing the ARK-hospital intervention in a single acute hospital. We provide evidence for both the feasibility of adapting the intervention according to local needs whilst maintaining fidelity to the core elements and acceptability of the intervention to front-line staff.

**Methods**

**Ethics**

Approvals were obtained from the South Central – Oxford C Research Ethics Committee (17/SC/0034) and Confidentiality Advisory Group (17/CAG/0015). The trial is registered with Current Controlled Trials (ISRCTN:12674243). This study has been reported in line with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)-AMS tool.

**Intervention description**

ARK has four components: an online tool, prescribing decision aid (supplementary figure 1), data collection and feedback process, and a patient leaflet that are summarised in table I. ARK implementation is led by an ARK Champion and Core Team, involving an AMS team member, and clinical staff considered essential to the local implementation of ARK. The implementation guidance sets out the main activities needed to establish ARK in seven
phases, beginning three months before kick-off, covering three months of implementation and then addressing sustainability (supplementary figure 2).

**Design**

This single site study focused on three key aspects; a) feasibility of adapting ARK to local needs, b) feasibility of key intervention components, and c) acceptability of ARK to the implementation team and the wider clinical team. The feasibility site was a selected Trust from a network of healthcare professionals involved in stakeholder consultations during the intervention development (Santillo et al., Journal of Antimicrobial Chemotherapy in press).

**Setting**

Brighton and Sussex University Hospitals NHS Trust (BSUHT) is an acute, medium-sized teaching hospital delivering secondary and tertiary services across two main sites. ARK was implemented on the larger 680-bed site, where approximately 75% of medical admissions come through a 32-bed acute medical unit (AMU). Medical patients are referred from primary care or the emergency department (ED). Patients who have an anticipated length of stay of >72 hours are transferred to an inpatient ward managed by an appropriate general or specialist team e.g. respiratory, elderly care, endocrine or gastroenterology.

Before implementation, the Trust’s total antibiotic prescribing (4,711 defined daily doses per 1000 admissions) reflected national figures (median in England 4,868 (range 1619 to 10475) in Q4 2016/17). The Trust used paper-drug charts including an antibiotic prescription page on which treatment duration was limited to five calendar days. The Trust had an AMS lead (0.2
whole time equivalent Consultant Microbiologist) and two full-time antimicrobial pharmacists working through an AMS committee, who met monthly with representation from infection control, service commissioners and trainees in infection medicine. The AMS committee reported upwards to the Trust’s Drugs and Therapeutics Committee (DTC) and the Infection Control Committee. In terms of education and training, the Trust used the MicroGuide™ platform as a mobile resource containing antibiotic prescribing guidelines and other AMS-related educational content. Prescribing practice was monitored through trust-wide audits, based on the NHS Safety Thermometer (NHS-ST) tool, whereby ward pharmacists collect data on antibiotic prescriptions for up to five patients per ward on a monthly basis. Antimicrobial consumption was monitored regularly and reported externally to Public Health England.

Data collection
Quantitative data on use of the online training module was collected automatically through LifeGuide. Point-prevalence data on use of the Decision Aid categories and antibiotic prescribing were collected from paper drug charts using the ARK data collection workbook, prior to implementation and at weeks 1, 2, 3, 4, 6, 8 and 12. Data was collected from all patients on the AMU, respiratory, elderly care, endocrine and gastroenterology wards who had received antibiotics during their current inpatient stay. Data were gathered for each antibiotic indication rather than individual agent. Indications were assumed to reflect infection as diagnosed by the prescriber and not defined further. Patient views on the patient leaflet were elicited through a brief questionnaire (supplementary materials) scored on a 1 to 7 Likert scale in a small sample of AMU patients who had been prescribed antibiotics and agreed to take part in a phone interview (Mowbray, et al. unpublished results).
Outcomes

Details of how the Core Team locally adapted and implemented each of the four ARK intervention components are reported alongside the relevant outcome measures. The champion identified key essential staff members who they felt would facilitate their clinical colleagues’ engagement with ARK. These included consultants and training-grade doctors from each relevant medical specialty, senior nurses and pharmacists working in the clinical areas where ARK was implemented and infection specialist doctors. The primary outcome was the proportion of preidentified key essential staff who completed the online training.

Other usage data for the online tool included the overall number of staff who completed it per 100 acute-beds, to reflect levels of staff engagement. Other outcomes reflected the process of implementation, specifically the proportion of initial prescriptions that: used the Decision Aid categories, were reviewed within 72 hours and had been stopped at review. These were all pre-specified in the protocol as secondary outcomes for the main trial. Other actions taken at review, i.e. switch agent (narrow/broaden), move from intravenous to oral route, or outpatient parenteral antimicrobial therapy (OPAT), were also considered in secondary analyses. Targets for ARK to be considered feasible and progress to the main trial were that >70% of staff identified by the champion as essential for ARK to be implemented should complete the online tool, and that >50% of prescriptions audited should have used the Decision Aid. These thresholds were chosen because with no evidence base for estimating the level of engagement necessary to achieve changes in prescribing behaviour, >70% engagement of key opinion leaders in the hospital and >50% use of the decision aid were felt to be required to impact intervention outcomes.
Analysis

Binary outcomes were assessed using univariable and multivariable logistic regression (or Fisher’s exact test if the outcome was identical for all prescriptions in one group), and other actions at review using multinomial regression. Evidence for variation across the implementation period (weeks 1-12) was assessed using Wald tests, and combined models comparing baseline versus post-implementation were used where there was no evidence of variation over time. Statistical analysis was performed using Stata version 14 (StataCorp, TX, USA).

Results

Core Team and essential clinical staff

At the feasibility site the Core team included: The Champion (Consultant in Infectious Diseases), the Trust’s AMS lead, two Acute Medicine Consultants, two Antimicrobial Pharmacists, two Acute Medicine Charge Nurses and three training-grade doctors. The Core team received access to the intervention materials in February 2017 to begin planning towards implementation on 18th April 2017. The team met four times over the 10 weeks to work through the guidance, assign and deliver key tasks. The Champion identified 33 key essential staff to promote the wider clinical teams’ involvement with ARK. These included 21 consultants (9 acute medicine, 4 microbiology and infection, 2 elderly care, 2 endocrine, 2 critical care, 1 each in respiratory and gastroenterology), 4 training-grade doctors in acute and general medicine including the ‘chief’ medical registrar, 4 pharmacists working in acute and infection medicine, and 2 acute medicine and 2 infection control nurses. All clinical staff were invited to a Grand Round, covering the background and practicalities, 4 weeks before implementation. Twelve separate ‘kick-off’ meetings were also held with individual clinical
teams, nursing staff, pharmacy staff and junior doctors. The details of how the Core Team locally adapted and implemented each of the four ARK intervention components can be found in table II.

**Online tool.** In terms of the primary outcome, the proportion of key essential staff who completed the online tool was 97% (32/33), exceeding the target of >70%. Including essential clinical staff, a total of 175 healthcare professionals registered to use the online tool and 132 completed it (19.4 per 100 acute beds). Of those completing the tool, 34% (45/132) were Consultants, 26% (34/132) were training-grade doctors, 19% (25/132) were nurses, 11% (14/132) were pharmacists or pharmacy technicians, 4% (5/132) were other healthcare professionals, and 7% (9/132) did not disclose their profession. Staff who completed the online tool logged into the website version a mean of 1.65 times (SD: 1.4; median 1, IQR 1-2, maximum 12) and spent a median of 14.3 minutes (IQR 10.1,28.2) on it. Although most users logged in only once (61%, 80/132), just under a third logged in twice (30%; 40/175), and 9% (12/132) logged in three times or more.

**Decision Aid.** Throughout the 12-week implementation, >75% of audited antibiotic prescriptions had applied the Decision Aid categories (figure 1), exceeding the 50% target, with no evidence of variation over time post-implementation (heterogeneity p=0.61). More prescriptions using the Decision Aid were categorised as “probable” rather than “possible”, but the proportion categorised as ‘possible’ increased over the 12-week implementation period (heterogeneity p=0.008) (figure 1).

**Data-collection and feedback.** During the 12-week implementation, the Core Team
undertook 32 point prevalence audits of antibiotic prescriptions using the ARK data collection tool, covering 107 prescriptions pre-implementation (baseline) and 588 post-implementation. Pre-implementation wards audited included acute medicine (27%; 29/107), respiratory (26%; 28/107), elderly care (32%; 34/107), endocrine (10%; 11/107), and haematology (5%; 5/107). Post-implementation prescriptions were audited on wards implementing ARK, namely elderly care (42%; 246/588), acute medicine (25%; 146/588), respiratory (16%; 92/588), endocrine (12%; 70/588) and gastroenterology (6%; 34/588). The Core Team delivered a total of 20 sessions to feedback antibiotic prescribing data across these four clinical teams.

**Patient leaflet.** All patients (N=15) rated the leaflet highly on providing all the information they needed (mean score (maximum 7)=6.5, SD=0.52), being helpful (6.4, SD=0.63), trustworthy (6.5, SD=0.64), and something they would recommend to others (6.2, SD=0.86), with 13/15 (87%) stating that they would be likely or extremely likely to recommend the leaflet to friends and family taking antibiotics in hospital. The commonest method of distribution was in discharge medication bags, meaning that most patients only received the leaflet on discharge.

**Impact on antibiotic review and decision making**

**Review within 72 hours of initial prescription**

Throughout the 12-week implementation, >96% of prescriptions were reviewed within 72 hours (figure 2), remaining approximately stable over time (Fisher’s exact p=0.80). Overall review rates increased from 91% (69/76) at baseline to 99% (450/457) post-implementation (odds ratio (OR) post vs pre-implementation=6.52 [95% CI 2.22,19.16], p=0.001).
**Stopping antibiotics**

The median antibiotic stop rate across audits post-implementation was 36% (range 29-40%) (figure 2) remaining relatively stable over time (heterogeneity p=0.87). Overall, the percentage stopping antibiotics by 72 hours increased from 9% (6/69) at baseline to 35% (156/450) post-implementation (OR=5.57 [95% CI 2.36,13.16], p<0.001). Post-implementation, antibiotic stop rates varied significantly according to the Decision Aid category, with 48% (51/106) of prescriptions categorised as “possible” stopped by 72 hours versus 29% (75/260) “probable” (OR (possible:probable)=2.29 [95% CI 1.44,3.64], p=0.001), compared with 36% (30/84) of prescriptions where the Decision Aid was not used.

**Other actions taken at review**

Over the 12-week implementation, the proportion of antibiotic prescriptions where no change was made declined (150/450 (33%) vs 37/69 (54%) baseline), as did the proportion switched to other agents (69/450 (15%) vs 15/69 (22%) baseline, p=0.71 vs ‘no change’) (figure 3). The proportion of antibiotics changed from intravenous to oral remained stable (75/450 (17%) vs 11/69 (15%) baseline; p=0.16 vs ‘no change’). There was no evidence that other actions depended on the Decision Aid category used (p>0.15). No patient started OPAT during the study.

**Discussion**

This study assessed the feasibility of implementing the novel, multifaceted ARK intervention which has been developed to address overprescribing of antibiotics to hospitalised patients. The four elements of the intervention were successfully introduced into AMS practice at a
medium-sized acute NHS hospital, facing typical pressures of under-staffing and patient burden. The percentage of pre-specified essential staff who completed the online tool greatly exceeded the target level for progression to full trial evaluation. The tool was also completed by a substantial number of front-line healthcare workers encompassing the main professional groups involved in antimicrobial treatment. The proportion of initial prescriptions using the Decision Aid also substantially exceeded the target threshold at all time points. Implementation of ARK was associated with a substantial and sustained increase in antibiotic stop rates over the 12-week study period. The sustained use of the Decision Aid and the Trust’s decision to adopt it into the antibiotic prescribing process, both long-term and Trust-wide, attest to the acceptability of the intervention. The increase in the proportion of prescriptions categorised as “possible” over time may be related to an improved understanding of the Decision Aid categories over the course of the intervention; the importance of the “possible” category in enabling prescribers to change antibiotic prescriptions at review was repeatedly emphasised during feedback sessions. Patient questionnaire responses indicated that patients received the leaflet very positively; this was also confirmed by qualitative interviews with patients (reported elsewhere; Mowbray et al., unpublished results). The AMS structures and processes were typical of acute NHS Trusts and remained so after the implementation of ARK, incorporating most core recommended elements.

Our study has important limitations. Most notably, as a feasibility study we were not seeking to establish whether the ARK intervention is effective in reducing antibiotic consumption itself. Antibiotic consumption across acute medical patients at a hospital varies markedly month by month and over time, with strong seasonality. Assessment of ARK’s impact on consumption requires thorough experimental evaluation, which will be achieved through a
nationwide stepped wedge cluster-randomised trial with prolonged follow-up to account for secular trends and to assess sustainability. For these reasons, we have not investigated patient-level outcomes. Robust assessment of safety in terms of preserving good clinical treatment outcomes while reducing antibiotic exposure is a key part of assessing a stewardship intervention and this will also be assessed in the full trial. Of note, the ARK intervention aims to support clinicians’ “review and revise” antibiotic decision making in line with ‘Start Smart then Focus’ recommendations, rather than demonstrate whether this is of itself a safe and effective strategy to mitigate risks of antimicrobial overuse. This approach closely follows recommendations followed in other healthcare systems, for example the CDC’s Core Elements of Hospital AMS Programmes which includes ‘antibiotic time outs’ to review prescribing decisions. Time-limiting initial antibiotic prescriptions has not, as far as we know, been evaluated in the NHS previously but has been found in the United States to reduce the total consumption of antibiotics and the use of inappropriate agents without negatively impacting mortality. As a measure of acceptability of the online learning, we could have reported the proportion of staff who completed it using either the number of staff who work in the areas where ARK was implemented or of staff invited to do the online learning. However, the way the learning was made available to healthcare workers involved in acute medicine and general medicine meant neither of these denominators could be obtained. Using the proportion of key essential staff gives a reliable but restricted measure. We can not discount the possibility that other staff members who could have been key influencers were not identified by the ARK Champion. However, this did not appear to have a negative impact on other study outcomes. The number of 19.4 staff trained per 100 acute beds is hard to interpret but the fact that 132 staff found time to do the online learning in a busy trust indicates it is not overly burdensome. As this study was conducted at a single acute hospital.
site, the results cannot be generalised to non-hospital settings and may be less applicable to hospitals with different infrastructures, which may be the case in other countries. Nonetheless, an important strength of our study is that we have been able to characterise the delivery and uptake of a novel multi-faceted intervention in a setting typical of the wider NHS environment in which its definitive evaluation will be undertaken. This study shows that the ARK intervention is adaptable and can be applied to other acute hospitals within the UK. It has informed how these sites can prepare for implementing ARK and has led to multiple additions to the implementation guidance e.g. more emphasis on how to incorporate the patient leaflet component. All materials developed in this feasibility study (such as slide sets, email and letter templates, poster and drug chart templates) form the basis of a resources set that is available to sites implementing ARK during the full trial. Another product has been the establishment of a national network involving Champions and their colleagues at sites involved in the full trial evaluation, a forum where they can communicate and a repository where they can share resources.

**Conclusions**

In conclusion, we have established the feasibility and acceptability of a complex behaviour change intervention aimed at increasing the rate of antibiotic stop decisions among acute medical admissions at a single acute NHS Trust. There is promising evidence that the ARK intervention may be able to motivate and support better adherence to existing guidance to stop antibiotics at review. A nationwide stepped-wedge randomised controlled trial is currently underway to establish the impact of this intervention on antibiotic consumption and patient outcome.
References


https://doi.org/10.1093/cid/cit212.

https://doi.org/10.1093/jac/dky041.


Table I. The four components of the ARK intervention

<table>
<thead>
<tr>
<th>Component</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Online tool</strong></td>
<td>A brief (7-10 minute) online tool on the University of Southampton LifeGuide platform (<a href="https://www.lifeguideonline.org">https://www.lifeguideonline.org</a>) that promotes motivation and confidence to implement “review and revise”, by discussing the risks and benefits associated with antibiotic treatment duration decisions and introducing the Decision Aid.</td>
</tr>
<tr>
<td><strong>Decision Aid</strong></td>
<td>Allows prescriber to acknowledge and record the degree of certainty around an initial antibiotic prescription and link this to the review decision, using two key antibiotic prescribing moments.</td>
</tr>
<tr>
<td>1. Initial prescription, at which point prescriptions are categorised as based on either:</td>
<td></td>
</tr>
<tr>
<td>- “possible” risk from infection (infection less likely but antibiotics are being prescribed until serious infection can be excluded) or</td>
<td></td>
</tr>
<tr>
<td>- “probable” risk of infection (infection is likely but more information is required before finalising the diagnosis/treatment)</td>
<td></td>
</tr>
<tr>
<td>2. Review, at which point prescriptions can either be <strong>stopped</strong> (where there is not a clear justification for continued treatment) or <strong>finalised</strong> (where a senior/specialist decides on agent, route and duration)</td>
<td></td>
</tr>
<tr>
<td><strong>Data collection and feedback process</strong></td>
<td>Uses point-prevalence data gathered with a Microsoft Excel workbook (Microsoft Corporation, Redmond, USA) to inform brief, frequent and supportive discussions with clinical teams about Decision Aid use and rates of stopping antibiotics, reinforcing learning about antibiotic prescribing decisions.</td>
</tr>
<tr>
<td><strong>Patient leaflet</strong></td>
<td>Explains the “review and revise” process, why antibiotics may be stopped, then potentially restarted, and gives safety-netting advice.</td>
</tr>
</tbody>
</table>

*See supplementary figure 1 for further explanation*
<table>
<thead>
<tr>
<th>Component</th>
<th>Local adaptation and implementation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Online tool</strong></td>
<td>• Approved by The Department of Medical Education to be available on the Trust’s e-learning platform</td>
</tr>
<tr>
<td></td>
<td>• Approximately 1 month before implementation, the ARK Champion invited the 33 members of essential staff to complete the tool</td>
</tr>
<tr>
<td></td>
<td>• On implementation, the Medical Director sent a trust-wide email inviting all medical staff to complete the tool</td>
</tr>
<tr>
<td></td>
<td>• Further email invitations and publicity within the 12-week implementation period also contained a link to the online tool</td>
</tr>
<tr>
<td><strong>Decision Aid</strong></td>
<td>• A new antibiotic prescription section of the paper drug chart was designed to incorporate the Decision Aid and containing an:</td>
</tr>
<tr>
<td></td>
<td>- Initial prescription section with “possible” and “probable” categories, allowing a maximum of 3 calendar days of antibiotics</td>
</tr>
<tr>
<td></td>
<td>- <strong>Finalised</strong> prescription section, allowing 6 calendar days to be administered</td>
</tr>
<tr>
<td></td>
<td>• In the 2 months prior to implementation it was piloted across a range of medical specialties and approval for the final design (supplementary figure 3) was gained from the Trust’s DTC before implementation</td>
</tr>
<tr>
<td></td>
<td>• During the study it was administered as an A4-size sticker placed over the existing antibiotic page of all drug chart in ED and AMU but post-implementation the DTC decided to incorporate the design permanently into the paper drug chart</td>
</tr>
<tr>
<td><strong>Data collection and feedback process</strong></td>
<td>• Forums used included handover meetings, multidisciplinary team meetings, governance meetings, teaching sessions and informally on the wards</td>
</tr>
<tr>
<td></td>
<td>• To reinforce understanding of the Decision Aid a number of brief case vignettes based on current or recent inpatients were also discussed (supplementary figure 4)</td>
</tr>
<tr>
<td><strong>Patient leaflet</strong></td>
<td>• Approved by the Trust’s DTC with the addition of local contact details and the Trust’s logo</td>
</tr>
<tr>
<td></td>
<td>• Printed copies available in the AMU’s doctors’ office, ward bays and clinical room</td>
</tr>
<tr>
<td></td>
<td>• Healthcare professionals were encouraged through the online tool, posters, email and feedback sessions, to give all patients who were prescribed antibiotics the leaflet</td>
</tr>
</tbody>
</table>
Acknowledgements

The following presentations have been made about ARK:


Conflicts of interest

None to declare. TP, SW, LY and ML designed the study and obtained funding. EC, KS, JI, MS, and FM were responsible for collecting and analysing the data, under the guidance of ML and LY, working closely with the other co-authors. EC and KS were responsible for drafting the manuscript, with support from ML and input from the other co-authors. All authors critically reviewed and approved the final manuscript.
Funding

This report is independent research funded by the National Institute for Health Research (Programme Grants for Applied Research, Antibiotic Reduction and Conservation in Hospitals (ARK-Hospital), RP-PG-0514-20015). The views expressed in this publication are those of the author(s) and not necessarily those of the National Health Service, the National Institute for Health Research or the Department of Health. ASW is supported by the NIHR Biomedical Research Centre, Oxford. The ARK online tool was developed using LifeGuide, which is funded by the NIHR Biomedical Research Centre (BRC), Southampton.